文献速递类风湿关节炎

高剂量与标准剂量灭活流感疫苗在类风湿关节炎患者中的免疫原性与安全性

Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial.
PubMed 文献 · Lancet Rheumatol · 2019-11-20

这项随机双盲活性对照试验在血清阳性类风湿关节炎成人中比较高剂量三价灭活流感疫苗(HD-TIV,每株60μg HA)与标准剂量四价疫苗(SD-QIV,每株15μg HA)。结果显示HD-TIV对A/H3N2、B/Bris及两个季节的A/H1N1血清转化率均更高,局部和全身不良事件两组相似,未报告严重不良事件,也未增加疾病活动度。

要点

  • HD-TIV对多个疫苗株的血清转化率优于SD-QIV
  • 两组局部和全身不良事件相似,未报告严重不良事件
  • 第3组(阿巴西普、托法替布或利妥昔单抗)人数不足,无法得出结论

核心结论

  • 在血清阳性类风湿关节炎患者中,HD-TIV安全且比SD-QIV更具免疫原性,为支持该人群使用HD-TIV提供了首批证据。

研究设计与样本

  • 治疗分层、随机、双盲、活性对照试验,2016-17和2017-18流感季在加拿大麦吉尔大学附属三家医院招募。
  • 纳入类风湿因子和(或)抗环瓜氨酸肽抗体阳性、正在使用传统或靶向合成DMARD或生物DMARD且入组前3个月治疗未调整的类风湿关节炎成人。
  • 按治疗分为3组后1:1随机接受SD-QIV或HD-TIV,主要结局为第28天各疫苗株血清转化率,安全性评估覆盖第0-186天。

主要发现

  • HD-TIV组相比SD-QIV组的血清转化比值比:A/H3N2为2·99(95%CI 1·46-6·11),B/Bris为1·95(1·19-3·22)。
  • A/H1N1血清转化比值比在2016-2017季为3·21(1·57-6·56),在2017-2018季为2·44(1·18-5·06)。
  • 第1组和第2组结果相似;第3组人数不足,无法得出结论。
  • 两组局部和全身不良事件相似,第0-28天未报告严重不良事件,两种疫苗均未增加类风湿关节炎疾病活动度。

关键数值与推荐

  • SD-QIV每株含血凝素15μg,HD-TIV每株含血凝素60μg。
  • 共邀请696例患者,279例随机并接种(SD-QIV 140例,HD-TIV 139例)。
  • 改良意向治疗分析纳入SD-QIV 136例、HD-TIV 138例。

临床怎么用

  • 对血清阳性且正在接受传统或靶向合成DMARD或生物DMARD治疗的类风湿关节炎患者,可考虑选用HD-TIV以增强免疫原性。
  • 接种前应评估患者当前抗风湿治疗方案,本试验结果主要适用于治疗稳定的患者。
  • 使用阿巴西普、托法替布或利妥昔单抗的患者证据不足,接种决策需个体化。

局限性

  • 第3组(阿巴西普、托法替布或利妥昔单抗)人数不足,无法得出该亚组结论。
  • 研究仅在加拿大三家医院开展,结果外推需谨慎。
  • 安全性随访至第186天,未评估更长期的免疫持久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with rheumatoid arthritis have increased risk of seasonal influenza and influenza-related complications but have reduced vaccine immunogenicity. It is unknown whether patients with rheumatoid arthritis would benefit from more immunogenic vaccine formulations. This study investigated the immunogenicity and safety of a high-dose trivalent inactivated influenza vaccine (HD-TIV) in patients with rheumatoid arthritis compared to a standard-dose quadrivalent influenza vaccine (SD-QIV). METHODS: This study was a treatment-stratified, randomised, double-blind trial to compare the immunogenicity and safety of SD-QIV (15 μg of haemagglutinin [HA] per strain) versus HD-TIV (60 μg of HA per strain) in adults with rheumatoid arthritis who are positive for rheumatoid factor or anti-cyclic citrullinated peptide, or both, recruited during the 2016-17 and 2017-18 influenza seasons at three hospitals affiliated with McGill University (Montreal, QC, Canada). Participants had received treatment for rheumatoid arthritis with conventional or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) or biological DMARDs, or combinations of them, were still on treatment at the time of enrolment, and their treatment had not been modified during the 3 months before enrolment. They were stratified into one of three groups according to treatment. Patients who, at enrolment, were taking conventional or targeted synthetic DMARDs (methotrexate, hydroxychloroquine, and sulfasalazine) as monotherapy or in combination were stratified to group 1; those who were taking a biological DMARD (anti-tumour necrosis factor or anti-interleukin 6), with or without methotrexate, hydroxychloroquine, or sulfasalazine (or a combination thereof) were stratified to group 2; and those who were taking abatacept, tofacitinib, or rituximab, with or without methotrexate, hydroxychloroquine, or sulfasalazine (or a combination thereof) were stratified to group 3. Participants were randomly allocated (1:1) to receive the SD-QIV or HD-TIV vaccine. Randomisation was based on a computer-generated allocation sequence, and participants, investigators, and research nurses responsible for safety assessments were masked to vaccine assignment. The primary outcome was the seroconversion rate (as measured by haemagglutination-inhibition assay) per strain at day 28. Analysis was done in the modified intention-to-treat population, which included all randomly assigned participants for whom seroconversion status was available. Safety was assessed throughout the surveillance period (day 0-186). This trial is registered at ClinicalTrials.gov, number NCT02936180. FINDINGS: Between Oct 24, 2016, and Dec 6, 2017, 696 patients with rheumatoid arthritis were invited to participate in the study and 279 were randomly assigned and vaccinated (140 [50%] received SD-QIV and 139 [50%] HD-TIV). 136 patients who received SD-QIV and 138 who received HD-TIV were included in the modified intention-to-treat anaysis. Patients who received HD-TIV were more likely to seroconvert than those who received SD-QIV: the odds ratio was 2·99 (95% CI 1·46-6·11) for seroconversion to strain A/H3N2, 1·95 (1·19-3·22) for seroconversion to strain B/Bris, 3·21 (1·57-6·56) for seroconversion to strain A/H1N1 (in 2016-2017), and 2·44 (1·18-5·06) for seroconversion to strain A/H1N1 (in 2017-2018). Similar results were observed in patients from groups 1 and 2; the number of individuals in group 3 was insufficient to draw conclusions. Local and systemic adverse events were similar in both vaccine groups, no serious adverse events were reported between days 0 and 28 in any group, and neither vaccine increased rheumatoid arthritis disease activity. INTERPRETATION: Our data suggest that in patients with seropositive rheumatoid arthritis, HD-TIV is safe and more immunogenic than SD-QIV. These results are the first evidence to support the use of the HD-TIV in these patients. FUNDING: The Arthritis Society-Canada.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Colmegna I, Useche ML, Rodriguez K, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. Lancet Rheumatol. 2019. PMID: 38258270. doi:10.1016/S2665-9913(19)30094-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。